期刊
ACTA NEUROPATHOLOGICA
卷 129, 期 4, 页码 597-607出版社
SPRINGER
DOI: 10.1007/s00401-015-1403-6
关键词
Low-grade glioma; Temozolomide; Hypermutator; Mismatch repair; MGMT
资金
- Accelerate Brain Cancer Cure
- Grove Foundation
- TDC Foundation
- Anne and Jason Farber Foundation
- UCSF Brain Tumor SPORE grant [NIH P50CA097257]
- Dutch Cancer Society (KWF) [2009-4470]
- foundation 'STOPHersentumoren'
- Edli foundation
- LiU Cancer Research Network
- Medical Research Council of Southeast Sweden
- National Institute Of General Medical Sciences [T32GM008568]
- National Institutes of Health [1T32CA15102201]
- National Cancer Institute [R01CA169316]
- Sontag Foundation
- NCI RO1 [R01 CA163687]
- Project for Development of Innovative Research on Cancer Therapeutics (P-Direct)
- Ministry of Education, Culture, Sports, Science and Technology of Japan [23134501, 24221011]
- Grants-in-Aid for Scientific Research [26293321, 23134501] Funding Source: KAKEN
Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined. DNA hypermethylation of the O (6) -methylguanine-DNA methyltransferase (MGMT) promoter is associated with an improved response to TMZ treatment, while inactivation of the DNA mismatch repair (MMR) pathway is associated with therapeutic resistance and TMZ-induced mutagenesis. We previously demonstrated that TMZ treatment of LGG induces driver mutations in the RB and AKT-mTOR pathways, which may drive malignant progression to secondary GBM. To better understand the mechanisms underlying TMZ-induced mutagenesis and malignant progression, we explored the evolution of MGMT methylation and genetic alterations affecting MMR genes in a cohort of 34 treatment-na < ve LGGs and their recurrences. Recurrences with TMZ-associated hypermutation had increased MGMT methylation compared to their untreated initial tumors and higher overall MGMT methylation compared to TMZ-treated non-hypermutated recurrences. A TMZ-associated mutation in one or more MMR genes was observed in five out of six TMZ-treated hypermutated recurrences. In two cases, pre-existing heterozygous deletions encompassing MGMT, or an MMR gene, were followed by TMZ-associated mutations in one of the genes of interest. These results suggest that tumor cells with methylated MGMT may undergo positive selection during TMZ treatment in the context of MMR deficiency.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据